NCT07382622

Effect of JointIQ on Joint Discomfort in Healthy Subjects

Effect of JointIQ on Joint Discomfort in Healthy Subjects: A Randomized, Double-blind Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Chung Shan Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of astragaloside supplementation on joint discomfort in healthy adults. The primary goal is to determine if daily intake of astragaloside can improve knee joint function and reduce discomfort over a 12-week period. Participants will be randomly assigned to receive either an astragaloside capsule or a placebo capsule once daily. Aim to see if those taking astragaloside experience better mobility and fewer joint-related symptoms compared to those in the placebo group.

Detailed description

The purpose of this randomized, double-blind clinical trial is to investigate the efficacy of astragaloside supplementation in enhancing joint health and physical function among healthy individuals aged 20 to 70 years. Study Design and Procedures: Participants will be randomized into two groups: the intervention group (astragaloside) and the control group (placebo). Each participant will be instructed to consume one capsule daily after a meal for 12 weeks. The study aims to address the following objectives: Physical Function Assessment: To evaluate changes in knee joint mobility and strength using the Single-Leg Step-Down (SLSD) test and Range of Motion (ROM) measurements. Subjective Symptoms and Quality of Life: To assess improvements in knee-related symptoms through the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire. Biological Markers: To analyze blood biomarkers related to joint health and systemic response. Comparative analysis between the astragaloside and placebo groups will be conducted to determine the statistical significance of the supplement's impact on joint function and discomfort.

Conditions

• Joint Discomfort

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Astragaloside	Participants in the Astragaloside Group will receive one astragaloside capsule orally once daily after meals for 12 weeks. The capsule contains the active compound astragaloside, a component of the traditional herb Astragalus. Participants will be asked to continue their usual diet and physical activity levels during the study.
DIETARY_SUPPLEMENT	Maltodextrin (Placebo)	Participants in the Placebo Group will receive one maltodextrin capsule orally once daily after meals for 12 weeks. The capsule is identical in appearance to the astragaloside capsule but contains no active astragaloside. Participants will be asked to continue their usual diet and physical activity levels during the study.

Timeline

• Start date: 2024-10-24
• Primary completion: 2025-10-09
• Completion: 2025-10-09
• First posted: 2026-02-03
• Last updated: 2026-02-03

Locations

1 site across 1 country: Taiwan